Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProAgio + gemcitabine + nab-paclitaxel
- Development stage
- Phase 1
- Lead developer
- ProDa BioTech
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
ProAgio + gemcitabine + nab-paclitaxel is an investigational combination therapy consisting of ProAgio, a novel protein-based drug (ACT50) that selectively binds to integrin αvβ3 on cancer-associated fibroblasts (CAFs) and induces their apoptosis, combined with gemcitabine, a nucleoside analog that inhibits DNA synthesis, and nab-paclitaxel (nanoparticle albumin-bound paclitaxel), a microtubule inhibitor. The combination is being studied as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC), aiming to enhance antitumor activity by targeting both the tumor stroma (via ProAgio) and tumor cells (via chemotherapy). This regimen is under investigation in an open-label Phase I/Ib trial to assess safety, pharmacokinetics, and preliminary efficacy[1][3][5][6].
- Other names
- G-nPgemcitabine and nab-paclitaxelnab-paclitaxel
02
Targets
CDA (Cytidine deaminase)αVβ3 (Integrin αVβ3)MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ProAgio + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProAgio + gemcitabine + nab-paclitaxel.